No Data
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
H.C. Wainwright Maintains Medicenna Therapeutics(MDNAF.US) With Buy Rating, Maintains Target Price $2.5
Updated MDNA11 Monotherapy and Combination Clinical Data From the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference
Medicenna Therapeutics GAAP EPS of -C$0.05
Unlock the Full List
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long